vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and BrightSpire Capital, Inc. (BRSP). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $83.2M, roughly 1.0× BrightSpire Capital, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -17.3%, a 24.1% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs -0.4%). BrightSpire Capital, Inc. produced more free cash flow last quarter ($55.1M vs $6.5M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Oakley Capital Investments, is a large British investment trust focused on investments in mid-market companies in the business services, consumer, education and technology sectors. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
BLLN vs BRSP — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $83.2M |
| Net Profit | $5.7M | $-14.4M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | — |
| Net Margin | 6.8% | -17.3% |
| Revenue YoY | 117.4% | -0.4% |
| Net Profit YoY | 138.3% | 27.3% |
| EPS (diluted) | $0.10 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $83.2M | ||
| Q3 25 | $83.5M | $83.9M | ||
| Q2 25 | — | $85.9M | ||
| Q1 25 | — | $77.6M | ||
| Q4 24 | $45.1M | $83.5M | ||
| Q3 24 | $38.4M | $88.2M | ||
| Q2 24 | — | $91.4M | ||
| Q1 24 | — | $95.8M |
| Q4 25 | — | $-14.4M | ||
| Q3 25 | $5.7M | $984.0K | ||
| Q2 25 | — | $-23.1M | ||
| Q1 25 | — | $5.3M | ||
| Q4 24 | $-11.5M | $-19.7M | ||
| Q3 24 | $-14.9M | $12.7M | ||
| Q2 24 | — | $-67.9M | ||
| Q1 24 | — | $-57.1M |
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 57.1% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 11.5% | -1.7% | ||
| Q2 25 | — | -54.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | 17.0% | -24.9% | ||
| Q3 24 | -32.9% | 13.2% | ||
| Q2 24 | — | -74.9% | ||
| Q1 24 | — | -59.4% |
| Q4 25 | — | -17.3% | ||
| Q3 25 | 6.8% | 1.2% | ||
| Q2 25 | — | -26.9% | ||
| Q1 25 | — | 6.9% | ||
| Q4 24 | -25.5% | -23.7% | ||
| Q3 24 | -38.8% | 14.4% | ||
| Q2 24 | — | -74.2% | ||
| Q1 24 | — | -59.6% |
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $0.10 | $0.00 | ||
| Q2 25 | — | $-0.19 | ||
| Q1 25 | — | $0.04 | ||
| Q4 24 | $-1.13 | $-0.16 | ||
| Q3 24 | $-1.47 | $0.09 | ||
| Q2 24 | — | $-0.53 | ||
| Q1 24 | — | $-0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $66.8M |
| Total DebtLower is stronger | $55.0M | $2.5B |
| Stockholders' EquityBook value | $-239.5M | $938.4M |
| Total Assets | $327.5M | $3.6B |
| Debt / EquityLower = less leverage | — | 2.63× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $66.8M | ||
| Q3 25 | $195.2M | $113.4M | ||
| Q2 25 | — | $154.3M | ||
| Q1 25 | — | $200.9M | ||
| Q4 24 | $191.5M | $302.2M | ||
| Q3 24 | — | $263.8M | ||
| Q2 24 | — | $203.3M | ||
| Q1 24 | — | $221.5M |
| Q4 25 | — | $2.5B | ||
| Q3 25 | $55.0M | $2.2B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | $51.5M | $2.5B | ||
| Q3 24 | — | $2.6B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.6B |
| Q4 25 | — | $938.4M | ||
| Q3 25 | $-239.5M | $976.4M | ||
| Q2 25 | — | $994.4M | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | $-251.7M | $1.0B | ||
| Q3 24 | $-242.9M | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | — | $3.6B | ||
| Q3 25 | $327.5M | $3.3B | ||
| Q2 25 | — | $3.4B | ||
| Q1 25 | — | $3.6B | ||
| Q4 24 | $302.1M | $3.7B | ||
| Q3 24 | — | $3.8B | ||
| Q2 24 | — | $3.8B | ||
| Q1 24 | — | $3.9B |
| Q4 25 | — | 2.63× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 2.27× | ||
| Q1 25 | — | 2.27× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | 2.36× | ||
| Q2 24 | — | 2.28× | ||
| Q1 24 | — | 2.17× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $73.0M |
| Free Cash FlowOCF − Capex | $6.5M | $55.1M |
| FCF MarginFCF / Revenue | 7.7% | 66.2% |
| Capex IntensityCapex / Revenue | 8.8% | 21.6% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $102.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $73.0M | ||
| Q3 25 | $13.8M | $29.9M | ||
| Q2 25 | — | $17.4M | ||
| Q1 25 | — | $10.5M | ||
| Q4 24 | — | $103.4M | ||
| Q3 24 | — | $31.3M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | $24.6M |
| Q4 25 | — | $55.1M | ||
| Q3 25 | $6.5M | $27.4M | ||
| Q2 25 | — | $11.6M | ||
| Q1 25 | — | $8.0M | ||
| Q4 24 | — | $97.3M | ||
| Q3 24 | — | $28.3M | ||
| Q2 24 | — | $22.7M | ||
| Q1 24 | — | $22.2M |
| Q4 25 | — | 66.2% | ||
| Q3 25 | 7.7% | 32.7% | ||
| Q2 25 | — | 13.4% | ||
| Q1 25 | — | 10.3% | ||
| Q4 24 | — | 116.6% | ||
| Q3 24 | — | 32.1% | ||
| Q2 24 | — | 24.9% | ||
| Q1 24 | — | 23.2% |
| Q4 25 | — | 21.6% | ||
| Q3 25 | 8.8% | 2.9% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 7.3% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 2.5% |
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | 30.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.97× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.46× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
BRSP
Segment breakdown not available.
